Form 4: Intra-Cellular Therapies Executive Mark Neumann Reports Stock Transactions
SEC Form 4 Filing
EVP and Chief Commercial Officer of Intra-Cellular Therapies, Mark Neumann, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Summary
- Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, reported transactions involving common stock and restricted stock units.
- On March 6, 2025, 13,133 restricted stock units vested and were converted into common stock.
- Also on March 6, 2025, 5,572 shares were withheld by the issuer to cover tax obligations at a price of $131.19 per share.
- On March 10, 2025, 7,345 restricted stock units vested and were converted into common stock.
- Additionally, on March 10, 2025, 3,116 shares were withheld for tax obligations at a price of $131.24 per share.
- Following these transactions, Neumann directly owns 52,811 shares of Intra-Cellular Therapies common stock and no restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions, with no inherent positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is a common occurrence in publicly traded companies. It provides transparency into the trading activities of key personnel and is required by the SEC.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The vesting schedules and tax withholding practices described are typical for restricted stock unit grants.
- Similar filings can be observed for executives at comparable pharmaceutical companies like Eli Lilly, Pfizer, and AbbVie.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they primarily reflect the vesting of previously granted equity compensation.
- Shareholders may view the transactions as a routine part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 03/10/2022 | Reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. |
| 03/06/2023 | Reporting person was granted 39,398 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. |
| 03/06/2025 | 13,133 Restricted Stock Units vested and converted to common stock; 5,572 shares withheld for taxes at $131.19. |
| 03/10/2025 | 7,345 Restricted Stock Units vested and converted to common stock; 3,116 shares withheld for taxes at $131.24. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.